The efficacy of concurrent cisplatin and 5-flurouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervix.
10.3802/jgo.2008.19.2.129
- Author:
Il Jung CHOI
1
;
Moon Seok CHA
;
Eunku Seul PARK
;
Myung Seok HAN
;
Youngmin CHOI
;
Goo Hwa JE
;
Hyun Ho KIM
Author Information
1. Department of Obstetrics and Gynecology, Dong-A University College of Medicine, Busan, Korea. mscha@dau.ac.kr
- Publication Type:Original Article
- Keywords:
Concurrent chemoradiation (CCRT);
Locally advanced cervical cancer;
Bulky cervical mass;
Cisplatin;
5-fluorouracil
- MeSH:
Cisplatin;
Consolidation Chemotherapy;
Disease-Free Survival;
Fluorouracil;
Follow-Up Studies;
Humans;
Lymph Nodes;
Medical Records;
Pelvis;
Uterine Cervical Neoplasms
- From:Journal of Gynecologic Oncology
2008;19(2):129-134
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To evaluate the efficacy of concurrent chemoradiation (CCRT) using 5-flurouracil (5-FU) and cisplatin for locally advanced cervical cancer. METHODS: We reviewed the medical records of 57 patients with locally advanced cervical cancer (stage IIB-IVA and bulky IB2-IIA tumor) who underwent the CCRT at Dong-A University Hospital from January 1997 to June 2007. The CCRT consisted of 5-FU, cisplatin and pelvic radiation. Every three weeks, 75 mg/m(2) cisplatin was administered on the first day of each cycle and 5-FU was infused at the dose of 1,000 mg/m(2)/d from the second day to the fifth day of each cycle. Radiation was administered to the pelvis at a daily dose of 1.8 Gy for five days per week until a medium accumulated dose reached to 50.4 Gy. If necessary, the radiation field was extended to include paraaortic lymph nodes. Consolidation chemotherapy was performed using 5-FU and cisplatin. RESULTS: Fifty-seven patients were enrolled and the median follow-up duration was 53 months (range 7-120 months). The overall response rate was 91.5% (74% complete response and 17.5% partial response). The 5-year overall survival and 3-year progression free survival rates were 69.4% and 74.9%, respectively. During the follow-up period (median 23 months, range 7-60 months), fourteen patients were diagnosed as recurrent disease. CONCLUSION: CCRT with 5-FU and cisplatin which is the primary treatment for patients with locally advanced cervical cancer was effective and well tolerated.
